The groundbreaking rise of Sildenafil presented a considerable prospect for the market, but its patent has expired , creating a complex landscape. Alternative versions have entered the market , cutting into revenues and putting a strain on profit margins . While major healthcare companies maintain a stake in this sector , the outlook seems clouded